Johnson & Johnson wins EU approval for TECVAYLI-DARZALEX as myeloma treatment moves earlier
Europe has approved teclistamab plus daratumumab after MajesTEC-3 showed an 83.4% reduction in progression or death and a significant overall-survival advantage versus established regimens.
